Among different strategies proposed to bypass TKI resistance in EGFR-mutated NSCLC, targeting the VEGFR (vascular endothelial growth factor receptor) pathway appears to be an interesting approach. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.